JP2000191542A - Preventive/therapeutic agent for osteoporosis - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain the subject medicament having excellent efficacy and safe even if administered for a long period, and to obtain foods/drinks containing the above medicament. SOLUTION: This preventive/therapeutic agent for osteoporosis contains at least one kind of plant selected from the group consisting of Coleus plants, Ptychopetalum plants, Adenophora plants, Solanum paniculatum L., Dalbergia subcymosa Ducke, Bauhinia forficata Link, Bauhinia forficata subsp. pruinosa (Vog.) Fortunatoet Wunderlin, Cinnamomum zeylanicum Blume, Callicarpa japonica Thunb., Euongmusalatus Sieb., Clerodendron trichootomum Thumb., and Punia granatum L., or extract(s) therefrom. The agent which is excellent in bone resorption inhibitory effect and free from any side effect as well, is highly safe and effective for human use.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to an agent for preventing and treating osteoporosis. More specifically, the present invention relates to Coleus plants, Petikopetalum plants, Trichoderma genus plants, Julbeba, Veronica, Unica de Vaca, Perta de Vaca, Canela, Murasaxikib,
Euonymus, safe osteoporosis prevention containing plants or extracts thereof selected from the group consisting of whales and pomegranates,
Related to therapeutic agents.

[0002]

2. Description of the Related Art Osteoporosis is a disease in which bone, which is a component of bone, is reduced in bone density due to a decrease in calcium, and the bone becomes very brittle. Post-menopausal women in whom estrogen involved in bone metabolism rapidly decreases. It is more common in elderly people with reduced calcium metabolism. Currently, 4 million people in Japan
It is said that there are 5 million patients, which has become a serious problem in recent years with the aging of society.

[0003] Therapeutic agents for osteoporosis include direct administration of calcium preparations, use of vitamin K, calcitonin, and bisphosphonate for the purpose of suppressing bone resorption, and promotion of bone metabolism by promoting calcium absorption in the intestinal tract. Vitamin D3 administration (medical term library
Osteoporosis, Yodosha, 1995) is known.

[0004]

However, none of the therapeutic agents have satisfactory therapeutic effects. For calcitonin, drug resistance is likely to appear, oral administration is impossible, and vitamin D is not sufficient. Have the drawbacks of not being able to achieve any significant effects, being prone to hypercalcemia, inhibiting bone formation for bisphosphonates, and requiring very large amounts of calcium preparations. ing.

[0005] Therefore, there has been a demand for the development of an agent for preventing and treating osteoporosis which does not have the above-mentioned disadvantages and is safe even when administered for a long period of time.

[0006] The present invention has been made to meet the above-mentioned demands, and provides a drug and food and drink for preventing and treating osteoporosis which have excellent osteoporosis preventing and treating effects and which are safe even after long-term administration. The purpose is to:

[0007]

Means for Solving the Problems and Actions The present inventors have made intensive studies to achieve the above object, and as a result, surprisingly, a plant of the genus Coleus, a plant of the genus Ptychopetalum, and a genus of Adenophora have been found. Plant, Juluva (Solanum paniculatum L.),
Veronica (Dalbergia subcymosa)
Ducke), Una de Vaca (Bauhi)
nia forficata Link), Perta de Vaca (Bauhinia forficata)
subsp. prunosa (Vog.) Fortu
natoet Wunderlin, Canela (Cin
namumzelanicum Blume),
Murasaxikib (Calicarpajaponic)
a Thumb. ), Euonymus a
latus Sieb. ), Smelt (Cleroden)
Dron trichotomum Thumb. ) And pomegranate (Punica granatum L.), and found that they have excellent osteoporosis preventive and therapeutic effects on plants or extracts thereof, and have accomplished the present invention.

Coleus used in the present invention (Coleus)
s) The genus plant has been used as a folk medicine for a long time in regions such as India, Arab, Africa, and Brazil. Among them, Coleus forskory
skolli Briq. ), Coleus parviflorus Bent
h. ), Coleus amboinicus
mboinicusLour. ) Is particularly desirable from the viewpoint of osteoporosis prevention / treatment effect. Coleus forskolli Briq. Is used as a drug for heart, respiratory and nervous system diseases or abdominal pain, and is also eaten as a pickle in India. Coleus parviflorus
viflorus Benth. ) Have potato-like tuberous roots and are also edible. Coleus amboinicus Lo
ur. ) Is effective for sunstroke, hemorrhoids, etc., and is also used for flavoring dishes.

Coleus used in the present invention
Genus plants are not limited to those cultivated and native in these areas. For example, Coleus (Coleus) cultivated in Japan
us) genus plants are no different in terms of composition and effectiveness than those obtained from the above regions. It is also possible to use an organ obtained by a tissue culture technique such as a microtuber, adventitious bud, adventitious root, hairy root, callus, and the like.

[0010] Ptychopetarum (Ptychopeta)
Lum) plants have been used in the Amazon in South America since ancient times as folk medicines such as tonics, digestive aids, and diarrhea control.
Local name among them: Ptychopeta
lum olacoidesBenth. ) And closely related species (Ptychopetalum uncinatum A)
nselmino) has an excellent osteoporosis prevention / treatment effect and is particularly desirable. Caribbean ginseng (Adenop)
The hora) plant has been used as a folk medicine in East Asia and Southeast Asia for a long time.
nophora tetraphylla Fish
er), Toushazin (Adenophora str)
icta Miq. ), Carrot ginseng (Adeno)
phora triphylla var. japon
ica Hara, etc., but particularly from the viewpoint of the effect, turtle ginseng (Adenophora tr)
iphylla var. japonica Har
a) is desirable.

[0011] Juluveva (Solanum pani)
culatum L. ) Is native to Brazil and Argentina, and is used as a folk medicine for jaundice, fever, hepatitis, diabetes, etc., as a veronica (Dalbergia subcymo).
sa Ducke is a folk remedy for swelling of the uterus in the Amazon region and Peru, as a folk remedy for Bhahinia forficata Lin
k), Batahinia fo
rficata subsp. pruinosa (Vo
g. ) Fortunatoet Wunderlin)
Is mainly used in Brazil as a folk medicine for diabetes, anthelmintic, bronchitis, etc.

Further, cannella (Cinnamum z)
(Eylanicum Blume) is widely used as a spice in various places. Muraxiquib (Call
icarpa japonica Thumb. ), Euonymus alatus Sie
b. ), Magpie (Clerodendron tric)
hotum Thumb. ) Is generally planted as a garden tree in Japan. Pomegranate (Punica gr
anatum L .; ) Uses the fruit for food,
Peel, root bark, leaves, flowers, etc. are also used as medicines in China and Japan.

As the above-mentioned plant group, xylem, heartwood, bark, branch, leaf, root, seed, fruit, flower, etc. can be used.

Examples of the solvent used for obtaining the plant group extract include commonly used organic solvents such as methanol, ethanol, butanol, hexane, heptane, cyclohexane, ethyl acetate and acetone, and water. These can be used alone or in combination of two or more. Among these solvents, methanol, ethanol and water are particularly preferred.

[0015] The extraction can be carried out by a conventional method at a temperature of usually about 3 to 70 ° C. In addition to the solvent extraction, an extract obtained by supercritical extraction in which carbon dioxide is brought into a supercritical state can be similarly used. At this time, hexane, ethanol, or the like can also be used as an extraction aid.

The extract may be used as it is, or may be used as a diluent or as a concentrated extract, or may be prepared as a dry powder by freeze-drying or the like, or may be prepared into a paste.

It has been clarified that the above plant groups or their extracts significantly inhibit bone resorption by human parathyroid hormone, prostaglandin, and the present invention has been accomplished.
Accordingly, the present invention provides a safe osteoporosis preventive and therapeutic agent comprising one or more of the above-mentioned plant group or an extract thereof.

Hereinafter, the present invention will be described in detail. The prophylactic or therapeutic agent of the present invention may be used for the oral use of the above-mentioned plant group as it is or an extract thereof as it is. It may be used as an oral pharmaceutical or parenteral composition in combination with an acceptable pharmaceutical adjuvant.

Examples of the form of the oral pharmaceutical composition include tablets (including sugar-coated tablets and film-coated tablets), pills,
Granules, powders, capsules (including soft capsules)
And liquid preparations such as syrups. Such a composition is produced by a method known per se, a carrier usually used in the field of production,
It contains excipients.

[0020] Solid preparations can be prepared using conventional excipients (silicic anhydride,
Synthetic aluminum silicate, lactose, corn starch, crystalline cellulose, etc.), binders (carboxymethylcellulose, polyvinylpyrrolidone, etc.), lubricants (magnesium stearate, talc, etc.), disintegrants (starch, carboxymethylcellulose calcium, etc.), etc. Flavoring agents, sweetening agents, coloring agents and the like can be contained.

Liquid preparations include aqueous or oily suspensions,
It may be a solution, a syrup or the like, or a dried product that can be redissolved with a suitable vehicle before use. Such liquid preparations include commonly used emulsifiers (lecithin, sorbitan monooleate, etc.), emulsifiers (sorbitol syrup, methylcellulose, gelatin, etc.), non-aqueous vehicles (coconut oil, peanut oil, etc.), and other oxidizing agents. Inhibitors, colorants, flavors and the like can be included.

Examples of the form of the parenteral pharmaceutical composition include injections, intramuscular injections and infusions, ointments, gels, suppositories and the like. Injectables are known per se,
That is, it is produced by dissolving, suspending or emulsifying the above plant group extract in a sterile aqueous or oily liquid usually used for injections. Aqueous solutions for injection include physiological saline, isotonic solutions containing dextrose and other auxiliary liquids, and, if necessary, in combination with a suitable suspending agent, such as sodium carboxymethylcellulose, a nonionic active agent, and the like. Is also good. The prepared injection is usually filled in a suitable ampoule. Ointments, gels, suppositories and the like are also produced by a method known per se.

In addition to the above-mentioned compositions, the composition can be applied to foods and drinks such as gums, jellies, candies, chocolates and juices. Furthermore, it can be added to various other foods as a food additive.

Among the above-mentioned plant groups, from the viewpoint of the effect, in particular, a plant of the genus Coleus (Coleus forskolli Bri) is a member of the genus Coleus.
q. ), Coleus parviflorus (Coleus p
arviflorus Benth. ), Coleus amboinicus L
our. ), Ptychopeta (Ptychopeta)
lum) plant of the muirapuama (Ptychopet)
alum olacoides Benth. ) And closely related species (Ptychopetalum uncinatum)
Anselmino), a plant of the genus Trichinella ginseng (Adenophoratriphyll)
la var. japonica Hara, Veronica (Dalbergia subcymosa Du)
cke), Unha de Vaca (Bauhinia)
forficata Link), Egret (Cler)
odentron trichothum Thum
b. ) Is preferred, and more preferably Coleus forskolli Bri
q. ), Coleus parviflorus (Coleus p
arviflorus Benth. ), Muirapuama (Ptychopetalum olacoides)
Benth. ), Crowendron
trichothum Thumb. ), And among them, Coleus forskolli Br, a plant of the genus Coleus.
iq. ) Is most preferred.

Further, the compounding amount of the osteoporosis preventive and therapeutic agent of the present invention is 0.000% of the total amount of the preparation containing the active ingredient.
0001 to 10% (% by weight, hereinafter the same), especially 0.00
It is preferably in the range of 01 to 1%, and the compounding amount is 0.000%.
If less than 001%, sufficient effect cannot be expected and 10%
If the ratio exceeds the above range, it may be difficult to formulate the formulation, or the formulation stability of the formulation may not be maintained.

The dose of the plant group or the extract thereof is appropriately increased or decreased according to the method of administration, the number of administrations and the age, weight and sex of the patient. It is administered in the range of 0.001 to 1 g once to several times a day within this range.

Each of the above-mentioned compositions is combined with the above-mentioned plant group or an extract thereof, and a calcium agent having a known osteoporosis prevention / amelioration effect, calcitonin, bisphosphonate, growth hormone, vitamin D, vitamin K, soybean isoflavonoid, etc. Can also be used in combination, and further improvement in the effects of preventing and treating osteoporosis can be expected.

[0028] Each of the above-mentioned compositions may contain other active ingredients as long as they do not cause undesired interaction with the above-mentioned plant group or an extract thereof.

[0029]

EFFECT OF THE INVENTION The preventive and therapeutic agent for osteoporosis of the present invention is effective as a highly safe and preventive and therapeutic agent for human osteoporosis in humans, which is excellent in the effect of inhibiting bone resorption and has no side effects.

[0030]

EXAMPLES The present invention will be specifically described below with reference to Preparation Examples, Experimental Examples and Examples, but the present invention is not limited to the following Examples.

[Preparation of extract of plant of genus Coleus] Preparation Example 1: Coleus forskoli
forskolli Briq. 1 kg of dry root
With carbon dioxide in a supercritical state, 350 kg / cm 2 · 40
Extraction at 51 ° C. yielded 51 g of concentrated extract. Preparation Example 2: Coleus parviflorus (Coleus
parviflorus Benth. 1) of the dried roots was cold-soaked with 10 L of 99.5% ethanol three times for 2 days each to obtain an extract. The solvent was distilled off from this extract using an evaporator to obtain 104 g of a concentrated extract. Preparation Example 3: Coleus amboinicus (Coleus
amboinicusLour. 1 kg of dried leaves
Was cold-immersed in 10 L of 99.5% ethanol three times for 2 days each to obtain an extract. The solvent was distilled off from this extract using an evaporator to obtain 132 g of a concentrated extract.

[Ptychopetm (Ptychopet)
Production of an extract of a plant of the genus alum)] Preparation Example 4: Ptychopetalu
molacoides Benth. 1) was dried and soaked three times with 10 L of 70% ethanol for 2 days each to obtain an extract. The solvent was distilled off from this extract using an evaporator to obtain 183 g of a concentrated extract.

[Adenophor
a) Production of an Extract of the Genus Plant] Preparation Example 5: Ginseng (Adenophora)
triphyllavar. japonica Har
1 kg of the dried root of a) was cold-soaked with 10 L of methanol three times for 2 days each to obtain an extract. The solvent was distilled off from this extract using an evaporator to obtain 166.
g of concentrated extract was obtained.

[Uña de Vaca (Bauhin)
Production of Extract of ia forficata Link) Preparation Example 6: Una de Vaca (Bauhinia)
1 kg of dried leaves of ForficataLink
The extract was cold-immersed in 0 L of 70% ethanol three times for 2 days each to obtain an extract. The solvent was distilled off from this extract using an evaporator to obtain 175 g of a concentrated extract.

[Crowendront]
richotom Thumb. Preparation of an Extract of the Example) Preparation Example 7: Egret (Clerodendron tri
photographum Thumb. Dry ground part 1)
kg of 3 times with 10 L of methanol for 2 times each.
The extract was obtained by immersing in cold for each day. The solvent was distilled off from this extract using an evaporator to obtain 141 g of a concentrated extract.

[Pomegranate (Punica granatum)
mlL. Preparation of Extract of Example 1) Preparation Example 8: Pomegranate (Punica granatum)
L. ) Was dried and soaked in 10 L of 70% ethanol three times for 2 days each to obtain an extract. The solvent was distilled off from this extract using an evaporator to obtain 160 g of a concentrated extract.

[Preparation of Extracts of Jurbeva, Veronica, Canela, Perta de Vaca, Murasaxikib, and Euonymus] Preparation Example 9: Solunum panic
ulatum L. ), Veronica (Dalbergi)
a subcymosa Ducke), Cannella (Ci
nanmom zelanicum Blum
e), Batahinia fo
rficata subsp. pruinosa (Vo
g. ) Fortunatoet Wunderli
n), murasakisikib (Callicarpa jap
onica Thunb. ), Euonym (Euonym)
us altus Sieb. Each of the plants was extracted according to Preparation Example 7 to obtain concentrated extracts.

[0038]

[Experimental Example 1] A study was performed using a mouse skull. That is, the skull of a BALB / c mouse newborn (about 5 days) was excised and divided into two parts, each of which was placed in 3 ml of 0.1% bovine serum albumin (hereinafter BSA) -containing α-MEM cell culture medium. Precultured for 24 hours in a CO2 incubator. Thereafter, 5 μM of prostaglandin E2 (hereinafter, PGE2) was applied to one of the divided skulls, and Coleus forskory of Preparation Example 1 was used.
skolli Briq. ) The extract was added to the concentration shown in Table 1 below. In addition, the same amount of PGE2 was added to the other skull and cultured for 48 hours in a CO ₂ incubator. Thereafter, the medium was collected, and Ca ²⁺ released into the medium was measured using Ciba Corning 550. Table 1 shows the results. In addition, the result shows that the mouse skull
The group in which only GE2 was added was used as a control group, and the bone resorption inhibiting effect of each drug was shown.

[0039]

[Table 1]

[0040]

[Experimental Example 2] The study was performed using a mouse skull. That is, the skull of a BALB / c mouse newborn (about 5 days of age) was excised and divided into two parts, each of which was CO _{2 in} a medium for culturing 10% FBSα-MEM cells containing 3 ml of 10 units / ml of heparin for 24 hours. Precultured in an incubator. Thereafter, 10 nM of human parathyroid hormone (hereinafter, PTH) was added to one of the divided skulls, and Coleus parviflorus of Preparation Example 2 was used.
rviflorus Benth. ) Extracts are listed in Table 2 below.
Was added so as to have a concentration indicated by. Further, the same amount of PTH was added to the other skull and cultured for 48 hours in a CO ₂ incubator. Thereafter, the medium was collected, and Ca ²⁺ released into the medium was measured using Ciba Corning 550. Table 2 shows the results. In addition, the result shows the bone resorption inhibitory effect of each chemical | medical agent, making the mouse | mouth skull a PTH only addition group a control group.

[0041]

[Table 2]

[0042]

[Experimental Example 3] The study was performed using a mouse skull. That is, the skull of a BALB / c mouse newborn (about 5 days) was excised and divided into two parts, each of which was placed in 3 ml of 0.1% bovine serum albumin (hereinafter BSA) -containing α-MEM cell culture medium. Precultured for 24 hours in a CO ₂ incubator. Then, 5 μM of prostaglandin E2 (hereinafter, PGE2) was added to one of the divided skulls, and Coleus ambinix of Preparation Example 3 was used.
oinicus Lour. ) The extract was added to the concentration shown in Table 3 below. In addition, the same amount of PGE2 was added to the other skull and cultured for 48 hours in a CO ₂ incubator. Thereafter, the medium was collected, and Ca ²⁺ released into the medium was measured using Ciba Corning 550. Table 3 shows the results. In addition, the result shows the bone resorption inhibitory effect of each chemical | medical agent, using the mouse | mouth skull as a control group with only PGE2 added.

[0043]

[Table 3]

[0044]

[Experimental Example 4] The study was performed using a mouse skull. That is, the skull of a BALB / c mouse newborn (about 5 days) was excised and divided into two parts, each of which was placed in 3 ml of 0.1% bovine serum albumin (hereinafter BSA) -containing α-MEM cell culture medium. Precultured for 24 hours in a CO ₂ incubator. Thereafter, 5 μM of prostaglandin E2 (hereinafter referred to as “PGE2”) was added to one of the divided skulls, and mutapuarma (Ptychopetalum o) of Preparation Example 4 was added.
lacoides Benth. ) The extract was added to the concentration shown in Table 4 below. In addition, the same amount of PGE2 was added to the other skull and cultured for 48 hours in a CO ₂ incubator. Thereafter, the medium was collected, and Ca ²⁺ released into the medium was measured using Ciba Corning 550. Table 4 shows the results. In addition, the result shows the bone resorption inhibitory effect of each chemical | medical agent, using the mouse | mouth skull as a control group with only PGE2 added.

[0045]

[Table 4]

[0046]

[Experimental Example 5] The study was performed using a mouse skull. That is, the skull of a BALB / c mouse newborn (about 5 days of age) was excised and divided into two parts, each of which was CO _{2 in} a medium for culturing 10% FBSα-MEM cells containing 3 ml of 10 units / ml of heparin for 24 hours. Precultured in an incubator. Thereafter, one of the divided skulls was put on 10 nM of human parathyroid hormone (hereinafter PTH) and the ginseng (Adenophora tr.
iphylla var. japonica Har
a) The extract was added to the concentration shown in Table 5 below. The same amount of PTH was added to the other skull,
The cells were cultured for 8 hours in a CO ₂ incubator. afterwards,
The medium was collected, and Ca ²⁺ released into the medium was measured using Ciba Corning 550. Table 5 shows the results.
In addition, the result shows the bone resorption inhibitory effect of each chemical | medical agent, making the mouse | mouth skull a PTH only addition group a control group.

[0047]

[Table 5]

[0048]

[Experimental Example 6] A study was performed using a mouse skull. That is, the skull of a BALB / c mouse newborn (about 5 days) was excised and divided into two parts, each of which was placed in 3 ml of 0.1% bovine serum albumin (hereinafter BSA) -containing α-MEM cell culture medium. Precultured for 24 hours in a CO ₂ incubator. Thereafter, 5 μM of prostaglandin E2 (hereinafter referred to as PGE2) was added to one of the divided skulls, and Bauhinia fo of Preparation Example 6 was used.
rficata Link), the heron of Preparation Example 7 (Cl
erodendron trichotomum Th
umb. ), Pomegranate of Preparation Example 8 (Punica gra
Natum L. ), Jurbeba of Preparation Example 9 (Sol
anum paniculatum L. ), Veronica (Dalbergia subcymosa Duc)
ke), cannella (Cinnamum zeylan)
icum Blume), Perta de Vaca (Ba)
uhinia forficata subsp. pr
uinosa (Vog.) Fortunatoet W
underlin), Euonymusal (Euonymusal)
atus Sieb. ), Murasakikibu (Calli)
carpa japonica Thumb. ) Were added so as to have the concentrations shown in Table 6 below. In addition, the same amount of PGE2 was added to the other skull and cultured for 48 hours in a CO ₂ incubator. Thereafter, the medium was collected, and ^the Ca ²⁺ that has been released into the medium was measured using a Ciba Corning 550. Table 6 shows the results. In addition, the result shows the bone resorption inhibitory effect of each chemical | medical agent, making the control group the mouse skull added only PGE2.

[0049]

[Table 6]

[0050]

EXPERIMENTAL EXAMPLE 7 A group of Syrian hamster males (8 weeks old) were treated with 20 plants / day of an extract of each of the plants of Preparation Examples 1, 2, 3, 4, 5, 6, 7, 8, and 9 per day. And 20
0 mg / kg was orally administered and observed for life and death for 10 days, but no death was observed.

The following is an example of the formulation. [Formulation Example 1] Tablet A tablet having the following composition is produced by a conventional method. Composition in 1 tablet (200 mg) Preparation Example 1 Coleus forskoli extract 10.0 mg Corn starch 84.0 mg Lactose 100.5 mg Hydroxypropylcellulose (HPC-L) 5.0 mg Magnesium stearate 0.5 mg

[Formulation Example 2] Tablet A tablet having the following composition is produced by a conventional method. Composition in 1 tablet (200 mg) Preparation Example 1 Coleus forskoli extract 5.0 mg Preparation example 7 Egret extract 5.0 mg Corn starch 84.0 mg Lactose 100.5 mg Hydroxypropylcellulose (HPC-L) 5.0 mg Stearic acid 0.5mg magnesium

Formulation Example 3 Capsules A capsule having the following composition is produced by a conventional method. No. 1 hard gelatin capsule was used as the capsule. Composition in 1 capsule (200 mg per tablet) Preparation Example 2 Coleus parviflorus extract 20.0 mg Corn starch 60.0 mg Lactose 110.0 mg Hydroxypropylcellulose (HPC-L) 10.0 mg

Formulation Example 4 Capsules Capsules having the following composition are produced by a conventional method. No. 1 hard gelatin capsule was used as the capsule. Composition in 1 capsule (1 tablet, 200 mg) Preparation Example 2 Coleus parviflorus extract 10.0 mg Preparation example 4 Muirapuama extract 10.0 mg Corn starch 60.0 mg Lactose 110.0 mg Hydroxypropylcellulose (HPC-L) 10.0 mg

[Formulation Example 5] Oral liquid preparation An oral liquid preparation having the following composition is produced by a conventional method. Composition in 1 ampoule (1 bottle, 100 ml) Preparation Example 3 Coleus amboinicus extract 0.1% Sorbit 14.0% Sodium benzoate 0.1% Flavor 1.0% Purified water Residue −−−−−−−−−−−−−−−−−−−−−−−−−− 100.0%

[Formulation Example 6] Oral liquid preparation An oral liquid preparation having the following composition is produced by a conventional method. Composition in 1 ampoule (1 bottle 100 ml) Preparation Example 8 Pomegranate extract 1.0% Preparation Example 9 Euonymus extract 0.1% Sorbit 12.0% Sodium benzoate 0.1% Fragrance 1.0% Purified water residue −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−− 100.0%

[Formulation Example 7] Ointment An ointment having the following composition is produced by a conventional method. White petrolatum 10.0% Stearyl alcohol 10.0% Propylene glycol 2.0% Preparation example 4 Muira puama extract 0.3% Preparation example 5 Triganella ginseng extract 0.7% Calcium carbonate 0.8% Polyethylene glycol # 4000 25. 0% Polyethylene glycol # 400 40.0% Ethanol Residual ---------------------------------------- Total 100.0%

[Formulation Example 8] Ointment An ointment having the following composition is produced by a conventional method. White petrolatum 10.0% Stearyl alcohol 10.0% Propylene glycol 2.0% Preparation example 1 Coleus forskoli extract 0.1% Preparation example 9 Juluveva extract 0.9% Calcium carbonate 0.8% Polyethylene glycol # 4000 25.0% Polyethylene glycol # 400 40.0% Ethanol Residual ----------------------------------------------------------- Total 100.0%

Formulation Example 9 Gel Preparation A gel preparation having the following composition is produced by a conventional method. Preparation Example 3 Coleus amboinicus extract 0.5% Preparation example 9 Canela extract 0.5% Carbopol 940 1.0% Sodium hydroxide 0.25% Sorbitan monostearate 5.0% Ethanol 7.0% Glycerin 23.0% Purified water Residue-------------------------Total-100.0%

[Prescription Example 10] Suppository A suppository having the following composition is produced by a conventional method. Preparation Example 6 Una de Vaca extract 0.5% Cocoa butter 47.0% Cholesterin 3.0% Glycerin Remaining ------------------------------- −−−−−−−− Total 100.0%

[Prescription Example 11] Suppository A suppository having the following composition is produced by a conventional method. Preparation 9 Perta de Verka extract 0.7% Preparation 9 Muraxikib extract 0.3% Cocoa butter 47.0% Cholesterin 3.0% Glycerin Remaining ------ −−−−−−−−−−−−−−−−−−−− Total 100.0%

 ────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Hiroshi Akimoto 1-3-7 Honjo, Sumida-ku, Tokyo F-term in Lion Corporation (reference) 4C088 AB12 AB30 AB33 AB38 AB48 AB59 AB99 AC03 AC04 AC05 AC06 AC11 BA08 BA09 BA10 MA07 NA14 ZA97

Claims (1)

[Claims] 1. A plant belonging to the genus Coleus, a plant belonging to the genus Ptychopetalum, a plant belonging to the genus Adenophora, and a solulum paniculatum (Solanum paniculatum)
L. ), Veronica (Dalbergia subcy)
Mosa Ducke), Una de Vaca (B
Auhinia forficata Link), Perta de Vaca (Bauhinia forfic)
ata subsp. prunosa (Vog.) F
ortunatoet Wunderlin, Cannella (Cinnamomum zylanicum Bl)
ume), murasakisikib (Callicarpa j)
aponica Thunb. ), Euonymus (Euon)
ymusalatusSieb. ), Magpie (Cler)
odentron trichothum Thum
b. ) And pomegranate (Punica granatum)
L. ) A prophylactic or therapeutic agent for osteoporosis, comprising one or more plants selected from the group consisting of: